420 related articles for article (PubMed ID: 20603408)
21. Myths, facts and scope of spinal cord tolerance dose revision in Intensity modulated SIB treatment of locally advanced head and neck cancer: A dosimetrical and radiobiological demonstration.
Patel G; Mandal A; Choudhary S; Mishra R; Shahi U; Mishra H
Cancer Radiother; 2021 Feb; 25(1):8-12. PubMed ID: 33293203
[TBL] [Abstract][Full Text] [Related]
22. Biological effective dose evaluation in gynaecological brachytherapy: LDR and HDR treatments, dependence on radiobiological parameters, and treatment optimisation.
Bianchi C; Botta F; Conte L; Vanoli P; Cerizza L
Radiol Med; 2008 Oct; 113(7):1068-78. PubMed ID: 18618074
[TBL] [Abstract][Full Text] [Related]
23. The tumor radiobiology of SRS and SBRT: are more than the 5 Rs involved?
Brown JM; Carlson DJ; Brenner DJ
Int J Radiat Oncol Biol Phys; 2014 Feb; 88(2):254-62. PubMed ID: 24411596
[TBL] [Abstract][Full Text] [Related]
24. Clinical implications of incomplete repair parameters for rat spinal cord: the feasibility of large doses per fraction in PDR and HDR brachytherapy.
Pop LA; Millar WT; Visser AG; van der Kogel AJ
Int J Radiat Oncol Biol Phys; 2001 Sep; 51(1):215-26. PubMed ID: 11516872
[TBL] [Abstract][Full Text] [Related]
25. Pulsed dose rate and fractionated high dose rate brachytherapy: choice of brachytherapy schedules to replace low dose rate treatments.
Visser AG; van den Aardweg GJ; Levendag PC
Int J Radiat Oncol Biol Phys; 1996 Jan; 34(2):497-505. PubMed ID: 8567354
[TBL] [Abstract][Full Text] [Related]
26. Synergistic effects of anti-PDL-1 with ablative radiation comparing to other regimens with same biological effect dose based on different immunogenic response.
Alinezhad M; Bakhshandeh M; Rostami E; Alimohamadi R; Mosaffa N; Jalali SA
PLoS One; 2020; 15(4):e0231507. PubMed ID: 32287292
[TBL] [Abstract][Full Text] [Related]
27. A challenge to traditional radiation oncology.
Fowler JF; Tomé WA; Fenwick JD; Mehta MP
Int J Radiat Oncol Biol Phys; 2004 Nov; 60(4):1241-56. PubMed ID: 15519797
[TBL] [Abstract][Full Text] [Related]
28. Obtaining organ-specific radiobiological parameters from clinical data for radiation therapy planning of head and neck cancers.
Quashie EE; Li XA; Prior P; Awan M; Schultz C; Tai A
Phys Med Biol; 2023 Dec; 68(24):. PubMed ID: 37903437
[No Abstract] [Full Text] [Related]
29. Radiobiology of hypofractionated stereotactic radiotherapy: what are the optimal fractionation schedules?
Shibamoto Y; Miyakawa A; Otsuka S; Iwata H
J Radiat Res; 2016 Aug; 57 Suppl 1(Suppl 1):i76-i82. PubMed ID: 27006380
[TBL] [Abstract][Full Text] [Related]
30. A systematic overview of radiation therapy effects in head and neck cancer.
Zackrisson B; Mercke C; Strander H; Wennerberg J; Cavallin-Ståhl E
Acta Oncol; 2003; 42(5-6):443-61. PubMed ID: 14596506
[TBL] [Abstract][Full Text] [Related]
31. Theoretical implications of incorporating relative biological effectiveness into radiobiological equivalence relationships.
Holloway RP; Dale RG
Br J Radiol; 2013 Feb; 86(1022):20120417. PubMed ID: 23385996
[TBL] [Abstract][Full Text] [Related]
32. Altered fractionation: limited by mucosal reactions?
Kaanders JH; van der Kogel AJ; Ang KK
Radiother Oncol; 1999 Mar; 50(3):247-60. PubMed ID: 10392810
[TBL] [Abstract][Full Text] [Related]
33. Quantitative assessment of radiation dose and fractionation effects on normal tissue by utilizing a novel lung fibrosis index model.
Zhou C; Jones B; Moustafa M; Schwager C; Bauer J; Yang B; Cao L; Jia M; Mairani A; Chen M; Chen L; Debus J; Abdollahi A
Radiat Oncol; 2017 Nov; 12(1):172. PubMed ID: 29116014
[TBL] [Abstract][Full Text] [Related]
34. Early mucosal reactions during and after head-and-neck radiotherapy: dependence of treatment tolerance on radiation dose and schedule duration.
Fenwick JD; Lawrence GP; Malik Z; Nahum AE; Mayles WP
Int J Radiat Oncol Biol Phys; 2008 Jun; 71(2):625-34. PubMed ID: 18474317
[TBL] [Abstract][Full Text] [Related]
35. A feasibility study of spatiotemporally integrated radiotherapy using the LQ model.
Kim M; Phillips MH
Phys Med Biol; 2018 Dec; 63(24):245016. PubMed ID: 30523816
[TBL] [Abstract][Full Text] [Related]
36. High-dose-rate brachytherapy may be radiobiologically superior to low-dose rate due to slow repair of late-responding normal tissue cells.
Orton CG
Int J Radiat Oncol Biol Phys; 2001 Jan; 49(1):183-9. PubMed ID: 11163513
[TBL] [Abstract][Full Text] [Related]
37. Dynamic optimization of a linear-quadratic model with incomplete repair and volume-dependent sensitivity and repopulation.
Wein LM; Cohen JE; Wu JT
Int J Radiat Oncol Biol Phys; 2000 Jul; 47(4):1073-83. PubMed ID: 10863081
[TBL] [Abstract][Full Text] [Related]
38. Biological equivalent dose assessment of the consequences of hypofractionated radiotherapy.
Jones B; Dale RG; Finst P; Khaksar SJ
Int J Radiat Oncol Biol Phys; 2000 Jul; 47(5):1379-84. PubMed ID: 10889393
[TBL] [Abstract][Full Text] [Related]
39. Intra-fraction dose delivery timing during stereotactic radiotherapy can influence the radiobiological effect.
Murphy MJ; Lin PS; Ozhasoglu C
Med Phys; 2007 Feb; 34(2):481-4. PubMed ID: 17388164
[TBL] [Abstract][Full Text] [Related]
40. A feasibility study: Selection of a personalized radiotherapy fractionation schedule using spatiotemporal optimization.
Kim M; Stewart RD; Phillips MH
Med Phys; 2015 Nov; 42(11):6671-8. PubMed ID: 26520757
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
